

HEALTHCARE SECTOR BULLETIN



March 2015: Issue 19

HEALTHCARE TRENDS & IMPACT STORIES

Country: Southeast Asia

Headline: ***Emerging Market Medical Education Goes Digital***

Summary: A shortage of skilled health workers is an acute and ongoing problem in many emerging markets. Weak medical education systems bear a major part of the blame, and typically suffer from two problems: A lack of qualified instructors, and weak or non-existent continuing medical education (CME) programs.

But a big opportunity for rapid progress has emerged as online medical education becomes increasingly common. In radiology, for instance, a growing number of hospitals around the world now use software that enables residents to receive virtual training from qualified practitioners anywhere in the world—a boon for places like Indonesia and Myanmar. Even surgery can now be taught remotely with technologies that combine virtual reality with AI techniques, an approach now being used in Bangkok. In Vietnam, a Harvard Medical School-affiliated NGO runs a video conferencing platform that connects HIV specialists in top Vietnamese hospitals with frontline community health workers. In many places, health workers are simply going online to improve their knowledge and skills. In the Philippines, for example, a group of doctors founded an online community called HealthXPh that uses social media for discussions about healthcare.

Health workers remain the frontline stewards of public health, and healthcare systems cannot function without them. New e-learning tools will increase the number of health workers globally and train them to provide high-quality care in places that desperately need it. Most likely, these same health workers will also advocate for many other necessary improvements in global health.

Link <http://ggmkts.com/insights/i-Emerging-market-medical-education-goes-digital>

Country: India

Headline: ***India Home Healthcare to expand to 16 cities by 2016; demands insurance cover for home healthcare***

Summary: India Home Healthcare (IHC) is increasing its footprint pan India and plans to expand to 16 cities by 2016. But it is now hoping that health insurance sector would recognise this service on similar lines that of hospitalisation.

The country's home healthcare service is viewed a promising business avenue with a massive growth scope. But bringing insurance into the home healthcare sector needs to be seen. Insurance companies focus on only hospitalisation reimbursements while for people opting for home healthcare post that, the costs have to be borne by the individual completely.

When insurance is extended to home healthcare, there will be a huge rise in people opting for healthcare services at home, benefiting everyone viz. hospitals, insurance companies, home healthcare players and the public. This will in fact be a milestone in the home healthcare field in India, Dr. Anitha Arockiasamy, president India Home Healthcare told Pharmabiz in an email.

The big challenge in the sector is that home healthcare in India is in a nascent stage and largely unorganised. Due to changing lifestyles and job profiles, home healthcare has been in great demand in both big and small cities. Availability of trained care-takers to cater to the huge demand is an area of concern.

Link <http://www.pharmabiz.com/NewsDetails.aspx?aid=86721&sid=1>

HEALTHCARE SECTOR NOTABLE TRANSACTIONS

Country: Indonesia

Headline: ***Quadria Capital invests in Indonesia's PT SOHO Global Health***

Summary: Indonesian pharmaceutical products company, PT SOHO Global Health (SOHO), has received funding from Asian healthcare investment firm Quadria Capital. The firm's first private equity investment in Indonesia is aimed to increase access to differentiated medicines of high quality within Indonesia and the Southeast Asia region.

SOHO, which is based in Jakarta, develops, manufactures, and markets evidence based natural medicine, and over-the-counter products primarily for Indonesia. In 2013, SOHO set up a joint venture partnership with a leading multinational pharmaceutical business, Fresenius Kabi, principally for the production and sale of innovative pharmaceutical liquid injectable products, and branded generics.

The shareholder and commissioner of SOHO, Tan Eng Liang said: "SOHO is at an important juncture in its evolution where we have established ourselves as a leader of high quality medicines. Our partnership with Quadria will help us in our next phase of growth as we look to materially expand our portfolio of products and strengthen the company."

Commenting on the agreement, Quadria Capital managing partner Abrar Mir said, "SOHO has a strong legacy within the Indonesian pharmaceutical industry and we hope to grow the company even further with our involvement. We are excited to work alongside the Tan Family and support a stellar management team led by La O'. We look forward to working closely with them to help build out the business and create long-term value for all stakeholders."

Links: <http://www.dealstreetasia.com/stories/quadria-cap-invests-in-indonesian-pharma-co-soho-4040/>

Country: India

Headline: ***Eye-Q Vision Gets USD 10m From Investors***

Summary: International Finance Corp. (IFC), a member of the World Bank Group, has invested USD 5.5 million in eye-hospital chain Eye-Q Vision. This equity investment is part of a USD 10 million financing round raised by Eye-Q. Nexus Venture Partners and Helion Venture Partners also invested in this round of funding, which will help expand access to high-quality and affordable eye-care services to non-metro cities. This is IFC's second healthcare venture capital investment in South Asia.

"IFC's global healthcare industry knowledge, expertise and long-term financing are valuable to our current expansion plans," said Rajat Goel, co-founder and CEO, Eye-Q Vision. Eye-Q currently provides eye-care services to nearly 350,000 patients a year, and plans to more than double patient reach over the next four years. Eye-Q will expand its network of super-specialty eye-care clinics. The company currently operates 28 clinics across the states of Delhi, Uttar Pradesh, Gujarat, Haryana, and Uttarakhand. The company plans to create skilled health-care jobs, a third of which are expected to be for women. "IFC's investment in Eye-Q will help increase and improve access to affordable health services," said Pravan Malhotra, IFC's venture capital lead for South and South-East Asia. Around one-fourth of Eye-Q's hospitals are already located in the low-income state of Uttar Pradesh.

Links: http://www.livemint.com/Companies/jwUeRDjdI9EXZp7aN7CkIJ/IFC-invests-55-million-in-EyeQ-Vision.html?utm_source=copy

TRANSACTION NEWS

Date	Headlines	Summary
16-Mar	Ybrain aims to launch wearable device for Alzheimer's in 2016 ahead of Series B funding – CEO (Source: Proprietary Intelligence)	<i>Ybrain, a privately held South Korean wearable medical device developer, plans to launch a wearable product for Alzheimer's disease by the first half of 2016 before it seeks Series B fundraising, said founder and CEO Lee Ki-Won. The company is currently focused on research and development to commercialize the product and generate revenues as it completed its Series A funding early this year. Ybrain expects to generate annual sales of KRW 10bn (USD 9m) after product launch, Lee said.</i>
16-Mar	FMI Medical Systems hopes to raise CNY 50m ahead of market approval licensing, sources say (Source: Proprietary Intelligence)	<i>Diva Laboratories [T4153:Taiwan], the Taiwanese medical and industrial flat monitor manufacturer, would issue further USD 3m-5m worth of shares by the end of 2015, said Tommy Wang, Vice President of the company. The proceeds are going to be spent on either building a brand new manufacturing plant or acquiring a Taiwanese manufacturing company. Diva at the moment employs 180 people. Diva Laboratories produces special flat screen monitors, mostly used in radiology, endoscopy and ultrasound imaging.</i>
16-Mar	Pharma Dynamics' 40% stake to be acquired by Lupin (Source: Company Press Release(s) (Edited))	<i>Lupin, an India-based drug company, announced on today that it has entered into an agreement to acquire the balance 40% equity stake in South African generics major, Pharma Dynamics (PD) from its founders. As per the agreement, the founders will exercise their put option before 31 March 2015, for the 40% equity stake they currently hold. On completion of this transaction, PD will become a wholly owned subsidiary of Lupin, subject to closing conditions. Headquartered in Cape Town, South Africa, PD was founded in 2001 and distributes a range of branded, generic prescription medicines and over-the-counter (OTC) products in SA as well as other key markets across the African continent.</i>
15-Mar	Arvida Group in talks for possible acquisition (Source: The Press)	<i>Arvida Group, the New Zealand-listed aged care business, is in talks for a possible acquisition, reported the Press. The report cited Bill McDonald, the chief executive of Arvida, who said that the company was in talks with several groups about a potential deal. The company was considering other aged care and retirement village operators as possible targets. In 2014, the company raised NZD 80m (USD 63.2m) from its initial public offering.</i>
14-Mar	Fortis Healthcare says will continue to explore alternate strategic opportunities related to RadLink-Asia following adverse CCS ruling on earlier deal (Source Stock Exchange Announcement(s) (Edited))	<i>With reference to the earlier announcement regarding Fortis (India-based Fortis Healthcare) to realise value from divestment of stake in RadLink-Asia to Medi-Rad Associates for SGD 137m (USD 98.4m), Fortis Healthcare has now informed the BSE that the Company's step down subsidiary at Singapore, Fortis Healthcare Singapore has received a decision from the Competition Commission of Singapore wherein following a review of the proposed transaction, involving the acquisition of RadLink-Asia and its subsidiaries by Medi-Rad Associates, an indirect wholly owned subsidiary of the Malaysia-based IHH Healthcare, the regulator (Competition Commission of Singapore) has indicated that if the proposed transaction is completed as contemplated, the combination may result in lessening of competition in the relevant market in Singapore. Consequently, Fortis will continue to explore alternate strategic opportunities related to RadLink and any significant decision around that shall be promptly intimated to exchanges.</i>

14-Mar Eye-Q to make two acquisitions this calendar year (Source: VCCircle)	<i>Eye-Q, a privately held Indian eye care chain, plans to close two acquisition deals this calendar year, Vccircle reported, citing Rajat Goel, Eye-Q's co-founder. According to Goel's comments cited by the paper, Eye-Q is seeking to acquire standalone eye hospitals, adding that the company has already initiated talks with several unnamed potential targets. Recently, the company raised INR 620m (USD 10m) from the World Bank arm, the International Finance Corporation (IFC), along with Eye-Q's existing backers -- Nexus Venture Partners and Helion Venture Partners.</i>
14-Mar Zhang Zhong Jing Pharmacy plans to launch IPO - report (translated) (Source: hexun.com)	<i>Zhang Zhong Jing Pharmacy [Zhang Zhong Jing Da Yao Fang], a Zhengzhou, Henan-based pharmacy, has plans to launch an IPO, according to a hexun.com report today. The Chinese language item, without identifying the source, added that the company has put listing on its agenda, but no further details were disclosed. Zhang Zhong Jing Pharmacy has a registered capital of CNY 60m (USD 9.6m).</i>
14-Mar Shinpoong Pharmaceutical drops JV agreement with LFB Biotechnologies due to financing issues (Source: Stock Exchange Announcement(s) (Edited))	<i>Shinpoong Pharmaceutical said that it has terminated an agreement with France's state-run LFB Biotechnologies regarding a joint venture for biomedicines. According to a statement to the stock exchange yesterday 13 March, Shinpoong has decided to drop the plan, because of its overall financial situation. The company has realized that the construction of a biomedicine plant needs a sizable additional investment than its earlier estimation, and considering its financing ability, Shinpoong has decided to withdraw from the partnership.</i>
13-Mar Radlink-Asia proposed acquisition by IHH Healthcare falls through (Source: Proprietary Intelligence)	<i>IHH Healthcare [KLSE: 5225], a Malaysia-based healthcare company, announced that the agreement to acquire Radlink-Asia from Fortis Healthcare Singapore has lapsed as some conditions precedent were not satisfied. Further to the announcement dated 12 September 2014, the Board of Directors of IHH Healthcare Berhad ("the Company") wishes to announce that the Sale and Purchase Agreement ("SPA") entered into between Medi-Rad Associates Ltd, an indirect wholly-owned subsidiary of the Company, and Fortis Healthcare Singapore Pte. Limited to acquire 100% of the issued ordinary shares in Radlink-Asia Pvt Ltd has lapsed and ceased to be of effect as of today due to the non-satisfaction of certain conditions precedent stipulated in the SPA.</i>
13-Mar Ship Healthcare seeks to buy disposable medical equipment distributor and pharmacy chain – COO Source: Proprietary Intelligence)	<p><i>Ship Healthcare Holdings [TYO:3360], a listed Osaka, Japan-based healthcare service provider, is looking to acquire a disposable medical equipment distributor and a domestic pharmacy franchise operator amid growing expectations for consolidation in these sectors, COO Hirotaoka Ogawa said. The JPY 145bn (USD 1.2bn) market cap company is receptive to advisory approaches and has previously worked with multiple advisors at banks and boutique M&A firms, he continued.</i></p> <p><i>Ship Healthcare, which sells catheters and custom-made disposable equipment kits for surgeries, expects demand for disposable medical devices for minimally invasive surgeries to increase as minimally invasive treatments are becoming a preferred option, Investor Relations representative Naoki Kouzuki said.</i></p>
13-Mar Karex will issue new shares to fund its acquisition, source says (Source: Proprietary Intelligence)	<i>Karex Berhad, the listed Malaysian condom maker, will issue new shares to raise funds to support its acquisition plans, a person familiar with the company said. It has received a management approval to dilute 10% stake through new share issuance, the person said. The proposed fundraise will take place in two to three years' time. Karex's spokesperson declined to comment. Currently, the company is</i>

		<p>conducting a private placement where it will issue 4.5m new shares with a price of MYR 3.9 per share.</p> <p>The company is in preliminary talks with several targets across Southeast Asia region but those have not advanced yet, the person said. It wants to expand its market share in Southeast Asia region where it does not have a strong presence. Globally, it accounts for one-sixth of total production in 2014 and exports to more than 110 countries across Africa, Asia, America and Europe, according to the company report. It wants to acquire a well-known brand in the local market, which could be developed together with Karex's brand.</p>
13-Mar	Medall Healthcare being eyed independently for possible 80% stake purchase by PE majors Advent, Apax, and Barings Asia - report (Source The Economic Times)	<p>Three global private equity (PE) funds, Advent International, Barings Asia, and Apax Partners, are each independently in talks to potentially acquire around 80% stake in Medall Healthcare, an Indian retail healthcare chain based in Chennai. The Economic Times cited three sources to report on the development. It was also noted that Medall's founder, Raju Venkataraman, will also dilute a portion of his stake in the deal. One of the sources cited earlier said that the due diligence process for a deal is now under way. The proceeds of the capital raise will be used for expansion purposes in South India.</p>
13-Mar	Monash IVF looking at Asia-based targets (Source: Australian Financial Review)	<p>Monash IVF, the Australian fertility business, is eager to grow in Asia, the Business Spectator reported. The report cited Monash Chief Executive James Thiedeman as saying that the company is currently looking at a couple of targets. Thiedeman said that in Malaysia the company plans to seek acquisitions among reproductive services clinics. Thiedeman noted that the business is also seeking to expand into areas including Indonesia, Thailand and Vietnam.</p>
13- Mar	ArmaGen seeks more than USD 40m Series B by mid-year 2015 – Exec (Source: Proprietary Intelligence)	<p>ArmaGen aims to raise a Series B upwards of USD 40m by mid-year 2015 to further advance its Hurler syndrome enzyme replacement therapy AGT-181, said Derek Kelaita, the company's vice president of business development. Conversations and due diligence processes are ongoing with a number of potential investors, he added. The Calabasas, California-based neurological disorder therapies developer has not yet set a valuation, though it is unlikely a majority stake would be sold, he said on the sidelines of this week's BIO-Europe Spring conference in Paris, France. The company's largest shareholder is Shire (NASDAQ:SHPG), followed by Boehringer Ingelheim Venture Fund, Takeda Ventures and Mitsui Global Investment, he said, noting there is no majority shareholder. He did not disclose the exact shareholding nor whether they will participate in the round.</p>
13- Mar	MS Help seeks buys to attain nationwide status, Biosphera among potential targets (Source: Proprietary Intelligence)	<p>MS Help Pharmacy, a Kazakhstan-based chemist's chain, is seeking a raft of peer acquisitions to boost its market presence, Zhanat Umarov chairman of Medservice Plus, the sole owner of MS Help, said. The management is scanning the whole country for potential acquisition targets as a part of an aggressive development strategy that envisages turning the group into a nationwide pharmacy chain, the executive explained.</p>
13- Mar	GemVax & KAEL to raise USD 5-10m by 2H15 for US expansion and R&D – CEO (Source: Proprietary Intelligence)	<p>GemVax & KAEL, a listed South Korean vaccine developer, is looking to raise USD 5m-10m by 2H15 through a stake sale to investors to fund its US expansion and research & development (R&D), said the company CEO SangJae Kim.</p> <p>Meanwhile, it will commercialize its therapeutic pancreatic cancer vaccine RIAVAX (GV 1001) this year since the product obtained the approval of the Ministry of Food</p>

and Drug Safety (MFDS) in September 2014, according to its investment relations report. GemVax has invested KRW 400bn for the RIAVAX trials, according to a local media report. It has completed Phase I, II and III trial tests in overseas countries including the US, France and the UK, as reported in November 2014. It has been working with UK-based Liverpool Cancer Trial Unit on GV 1001, according to a previous report by Mergermarket.

<p>13- Mar <i>DiNonA plans to launch IPO this year, obtains regulatory approval - report (translated) (Source: The Bell)</i></p>	<p><i>DiNonA, the South Korean antibody drug development company, plans to launch an initial public offering this year, the Bell reported. The Korean-language newspaper cited venture capital sector sources for the information. The sources said the company has obtained the necessary IPO approval through a technology assessment test last month. In South Korea, companies with a strong technology base can be permitted to list regardless of their financial performance. DiNonA plans to list on the KOSDAQ, a junior board of the local exchange, this year.</i></p>
<p>12- Mar <i>Vita 34 scouts out acquisitions and local partners in Asia, US – CEO (Source: Proprietary Intelligence)</i></p>	<p><i>Vita 34 [FRA: V3V], a German umbilical cord blood bank, is seeking acquisitions in the US and Asia as part of its international business expansion, Chief Executive Officer Andre Gerth said. As an example of the kind of targets the company would look for, Gerth pointed to Vita 34's latest acquisition of Austrian Vivocell in January 2015. It bought the German stem cell extraction firm Stellacure in December 2013. He declined to comment on the amount the company would spend on acquisitions.</i></p>
<p>12- Mar <i>Japan Post Holdings to sell two hospitals in Niigata and Hyogo to Japan-based medical corporations (Source: Company Press Release (Translated))</i></p>	<p><i>Japan Post Holdings announced separately on 11 March it will sell two hospitals in Niigata and Hyogo Prefectures to Japan-based medical corporations on 1 April 2015. Japan Post will sell Niigata Teishin Byoin to Niigata Rinko Hospital, and Kobe Teishin Byoin to Minami-Awaji Hospital. The value of the transactions was not disclosed in either release.</i></p>
<p>12- Mar <i>Shandong Jincheng Pharmaceutical and Chemical plans major asset restructuring, share trading halted (Source: Stock Exchange Announcement (Translated))</i></p>	<p><i>Shandong Jincheng Pharmaceutical and Chemical [Jin Cheng Yi Yao; SZ: 300233], a China-based listed company, said in a stock exchange announcement that it is planning a major asset restructuring. Share trading in Shandong Jincheng has been in halt since 5 January due to an unspecified major issue. The listed company confirmed today that it is planning a major asset restructuring. It is estimated that the company will publish the preliminary plan by 5 April. The market capitalization of Shandong Jincheng stands at CNY 4.9bn (USD 782.5m).</i></p>
<p>12- Mar <i>Lepu Medical Technology (Beijing) in talks to buy Beijing Hushengtang Pharmacy (Source: Stock Exchange Announcement (Translated))</i></p>	<p><i>Listed Lepu Medical Technology (Beijing) [Le Pu Yi Liao; SZ: 300003] said in a stock exchange announcement that it is in talks to buy Beijing Hushengtang Pharmacy [Hu Sheng Tang Da Yao Fang]. Beijing Hushengtang Pharmacy, set up in 2005, currently operates 11 chain pharmacies and two clinics.</i></p>
<p>12- Mar <i>WetTrust Korea seeking legal advisor in Germany for global expansion (Source Proprietary Intelligence)</i></p>	<p><i>WetTrust Korea (WetTrust), a privately held Gyeonggi-do, South Korea-based medical device company is seeking a legal advisor to start selling products in Germany by 2016, a company spokesperson said. It will retain a local law firm to ink a distribution agreement with German distributors, she said.</i></p> <p><i>WetTrust is currently applying for medical device class IIa clearance with the US Food and Drug Administration (FDA) and is in a process of obtaining CE Marking in order to sell in the US and Europe, she continued. It expects to receive approval this year and aims to start selling the products there as early as in 2016, she noted. The</i></p>

company's products have already been registered as Over-the-counter (OTC) Human Drugs with the FDA, she added. It eventually aims to open a subsidiary for sales and manufacturing somewhere in Europe, as manufacturing regionally can help boost European consumers' confidence in products, she added. Currently, all its products are manufactured in Korea and then exported, she said.

<p>12- Mar Schnell Biopharmaceuticals' largest shareholder terminates sale talks with Regen Beauty Medical Group - report (translated) (Source News1 Korea)</p>	<p>The largest shareholder of Schnell Biopharmaceuticals has terminated talks with Regen Beauty Medical Group regarding a potential sale of the listed South Korean pharmaceutical company, reported News1 Korea. Regen Beauty Medical Group is South Korean plastic surgery hospital operator.</p> <p>The Korean-language report cited an insider from Schnell Biopharmaceuticals as saying that it is not known why the negotiations broke off. It was reported earlier this year that the CEO and the largest shareholder of Schnell Biopharmaceuticals was in talks with Regen Beauty Medical to sell Schnell's stake. The CEO, Jae-seop Kim, and related parties jointly hold a 23.2% stake in Schnell Biopharmaceuticals. Schnell Biopharmaceuticals has a market cap of KRW 122.2bn (USD 110.1m).</p>
<p>12- Mar Astec Lifesciences denies report on company selling stake (Source: Stock Exchange Announcement(s) (Edited))</p>	<p>The Bombay Stock Exchange (BSE) had sought a clarification from Astec Lifesciences, an India-based drug company, with respect to a report on ET NOW earlier today, 11 March, titled "Company looking to sell stake, company open to selling off business, bring in strategic partner". Astec Lifesciences replied stating: "We remain fully committed to growing the operations of the company and are looking at a healthy growth this year.</p>
<p>12- Mar Dr Reddy's Laboratories declines to comment on report about possible purchase of India operations of UCB (Source: Stock Exchange Announcement(s) (Edited))</p>	<p>The Bombay Stock Exchange (BSE) had sought a clarification from Dr Reddy's Laboratories with respect to a report in the Economic Times earlier in the day, 11 March, titled "DRL may Buy UCB's India Ops for USD 135m". The newspaper, in turn, published information citing Reuters. Dr Reddy's replied stating: "We would like to state that we do not comment on market speculations.</p>
<p>11- Mar Invitro seeks buys to expand CIS operations, franchising deals also on offer – CEO (Source: Proprietary Intelligence)</p>	<p>Invitro, a Russian privately-held medical laboratory and diagnostic services provider, is seeking acquisitions that would expand its operations across several CIS markets, CEO Sergei Ambrosov said. Potential targets would include companies offering diagnostic services, the executive said without discussing possible deal valuations or specific timelines for deals. The targets search will be handled both in-house and via external consultants, the CEO noted. Apart from Russia, its core market, Invitro is also present in Belarus, Kazakhstan and Ukraine. The firm currently has about 700 laboratories across these countries, the executive added.</p>
<p>11- Mar Export Hydro receives letter of intent to be acquired by GrowPros (Source: Company Press Release(s))</p>	<p>GrowPros Cannabis Ventures Inc. (CSE:GCI), in accordance with our strategy as a diversified cannabis venture firm, has entered into an exclusive letter of intent with Export Hydro, a manufacturer and exporter of indoor gardening equipment based in Hong Kong. Export Hydro designs, manufactures, and distributes growing equipment specifically for the medicinal cannabis market.</p>
<p>11- Mar Sydney Ultrasound for Women acquired by Monash IVF for AUD</p>	<p>Monash IVF Group [ASX:MVF] announced a further expansion of its domestic women's imaging and diagnostics network with the acquisition of Sydney Ultrasound for Women ("SUFW"), according to a notice filed to the Australian Securities Exchange. SUFW is the leading specialist women imaging business in NSW, operating ten practices in the Sydney metropolitan area. The acquisition of</p>

	<p>30.1m (Source: Stock Exchange Announcement*)</p> <p>SUFW will complement the existing Monash Ultrasound for Women business in Victoria and Monash IVF Group's focus on women health, according to the statement. SUFW has been acquired by the Group for a total consideration of AUD 30.1m (USD 23.7m), the statement said.</p>
<p>11- Mar Beijing Yicheng Bioelectronics' PE shareholder Sequoia prepares exit, sources say (Source: Proprietary Intelligence)</p>	<p>Also eyeing domestic fitness center buys for geographical diversification In talks over sales JV or alliance in Southeast Asia Gunze, a listed Osaka, Japan-based textile maker, is considering acquisitions to strengthen its medical material operation and develop new healthcare-related products, Public & Investor Relations General Manager Osamu Tomioka said.</p>
<p>11- Mar Gunze considering medical material or healthcare-related buys (Source: Proprietary Intelligence)</p>	<p>TMC Life Sciences, the listed Malaysian healthcare operator, is acquiring BB Waterfront, an unlisted Malaysian company, for MYR 400m (USD 112m). The company made the following press release on the acquisition. The purchase consideration shall be settled by the issuance of 533,333,333 new TMC shares at an issue price of MYR 0.75 per Share, together with 266,666,666 free warrants. BBWF owns the Thomson Iskandar, a medical hub project located on 1.6ha of freeholdland in Johor Bahru. The freehold land is located at the Stulang Laut area, which is within 1km radius of the Malaysian CIQ complex located at the Causeway linking Singapore to Johor Bahru. The medical hub will be managed by Thomson International, a subsidiary of Thomson Medical Pvt Ltd, an experienced and reputable private hospital owner and operator in Singapore with more than 30 years' track record.</p>
<p>11- Mar Nichii Gakkan to continue China acquisition spree in nursery care segment, source says (Source: Proprietary Intelligence)</p>	<p>Nichii Gakkan, a listed Tokyo, Japan-based nursing care and education company, plans to beef up its presence in the nursery care segment in China through acquisitions, a person familiar with the situation said. The JPY 80bn (USD 659m) market cap company is currently exploring potential targets in the region and intends to actively acquire firms.</p>
<p>11- Mar Beijing Leadman Biochemistry's planned asset purchase via new share issue rejected by CSRC (Source: CSRC website)</p>	<p>The planned assets purchase of Beijing Leadman Biochemistry [Li De Man; SZ: 300289], a listed Chinese diagnostic products company, has been rejected, according to information on the China Securities Regulatory Commission (CSRC) website information tonight. The CSRC considers the asset acquisition document submitted by the listed company fails to provide an accurate and comprehensive description of the extent to which the target companies depend on its parent company and the subsequent impact on their sustainable profitability.</p>
<p>11- Mar Jilin Yatai (Group) subsidiary to acquire a 60.09% stake in Jiangsu Vcare Pharmaceutical at CNY 150m (Source: Stock Exchange Announcement (Translated))</p>	<p>Jilin Yatai Group Pharmaceutical Investment [Ya Tai Yi Liao Tou Zi], a subsidiary of the listed Jilin Yatai (Group) [Ya Tai Ji Tuan, 600881.SH], will acquire a 60.09% stake in Jiangsu Vcare PharmaTech [Wei Kai Er] at CNY 150m (USD 23.95m). According to a stock exchange announcement by Jilin Yatai (Group) dated 10 March, its subsidiary will acquire a 31.11% stake from the existing shareholders of Jiangsu Vcare PharmaTech, a privately held pharmaceutical company engaged in R&D and production of APIs and intermediates, at CNY 45m and will then make a capital investment of CNY 105m in the latter.</p>
<p>11- Mar Celltrion open for strategic investment only, no plan to invite financial investment (translated)</p>	<p>Celltrion, a listed South Korean bio similar developer, will be open for strategic investment only and no plan to invite financial investment, the Financial News Daily reported. The Korean daily cited president Jeong-jin Seo, who said in a press meeting yesterday (10 March), since he had scrapped a plan to sell his stake in the company, he would not put the company up for sale.</p>

*(Source: Financial News Daily
(Korea))*

11- Mar <i>Dr Reddy's Laboratories in discussions to acquire UCB's India operations for USD 135m – Newswire Round-up (Source: Newswire Round-up)</i>	<i>Dr Reddy's Laboratories, the India-based drug company, is in discussions to acquire Belgium-based pharmaceutical company UCB's India operations for around USD 135m, according to a newswire report. The Reuters report attributed the information to an unidentified source. The news report cited the source as noting that Dr Reddy will finance the acquisition with its cash balance. According to the UCB website, there are more than 450 employees at the India unit of the company, and the portfolio of its products in the country include those of allergies, respiratory disorders and epilepsy.</i>
11- Mar <i>Strides Arcolab to hold court-convened shareholder meeting 10 April to approve Shasun Pharmaceuticals' scheme of amalgamation with company (Source: Stock Exchange Announcement(s) (Edited))</i>	<i>India-based Strides Arcolab will hold a court-convened shareholder meeting 10 April to approve Shasun Pharmaceuticals' scheme of amalgamation with the Company. This information is contained in a Strides Arcolab stock-exchange filing made earlier today, 10 March.</i>
10- Mar <i>Nichii Gakkan to continue China acquisition spree in nursery care segment, source says (Source: Proprietary Intelligence)</i>	<i>Nichii Gakkan, a listed Tokyo, Japan-based nursing care and education company, plans to beef up its presence in the nursery care segment in China through acquisitions, a person familiar with the situation said. The JPY 80bn (USD 659m) market cap company is currently exploring potential targets in the region and intends to actively acquire firms.</i>
10- Mar <i>Guangzhou Improve Medical Instruments in share trading halt, planning significant assets restructuring (Source: Stock Exchange Announcement (Translated))</i>	<i>Guangzhou Improve Medical Instruments [Yang Pu Yi Liao, 300030.CHI], a listed Chinese medical equipment maker, will halt its share trading on 11 March due to planning a significant assets restructuring. The company stock exchange announcement tonight said it is expecting to disclose the draft plan or deal book by 10 April. The company has a market cap of CNY 4.999bn (USD 799m).</i>
10- Mar <i>Strand Life Sciences hires Oppenheimer for a USD 20m fundraise (Source: Proprietary Intelligence)</i>	<i>Strand Life Sciences, a genomics and personalised medicine company, has hired Oppenheimer for a USD 20m fundraise, said founder Vijay Chandru. The company is looking at roping in a marquee US based investor and wants to expand in the US markets, he added. Chandru did not respond to further queries. The company had briefly looked at a Series C fundraise in 2014 as well, and was expecting a valuation of USD 75m to USD 100m, as per a Mergermarket report.</i>
10- Mar <i>Beijing Chunlizhengda Medical Instruments raises USD 25m through Hong Kong IPO (Source: Stock Exchange Announcement*)</i>	<i>Beijing Chunlizhengda Medical Instruments, a Beijing-based orthopedic medical device company, announced that it has raised approximately HKD 195m (USD 25m) through its IPO in Hong Kong. The company currently intends to use the net proceeds in accordance with the purposes set out in the section headed "Future Plans and Use of Proceeds" in the IPO prospectus.</i>
10- Mar <i>Amneal intends to close partnership deals in Japan, Brazil and Indonesia</i>	<i>Amneal Pharmaceuticals is aiming to close multiple commercial partnership deals in Japan, Brazil and Indonesia by the end of this year (2015) for biosimilars and select</i>

	<p><i>by YE15 - exec (Source Proprietary Intelligence)</i></p> <p><i>complex generics in its portfolio, said Apurva Saraf, vice president, Global Operations and Business Development, on the sidelines of the recent World Generic Medicines Congress Europe in Madrid.</i></p>
<p>10- Mar Nantong Jinghua Pharmaceutical in share trading halt, planning significant assets restructuring (Source: Stock Exchange Announcement (Translated))</p>	<p><i>Nantong Jinghua Pharmaceutical [Jiang Hua Zhi Yao, 002349.SZ], a Jiangsu-based, listed Chinese pharmaceutical company, will continue the share trading halt on 11 March due to planning a significant assets restructuring. According to a company stock exchange announcement tonight, it has been in share trading halt since 25 February and is expecting to disclose the relevant deal information by 10 April. The company has a market cap of CNY 9.62bn (USD 1.536bn).</i></p>
<p>09- Mar Riei seeks targets to expand nursing care business and launch food delivery service – CEO Source: Proprietary Intelligence)</p>	<p><i>May also consider acquisitions in China to increase presence IPO in HK or Singapore could be among options Regularly approached with buyout offers Riei, a privately held Chiba, Japan-based nursing care operator, is seeking domestic acquisitions to expand its nursing care business and launch a food delivery service, President and CEO Hajime Kabasawa said. The family owned company, which has annual revenues of JPY 10bn (USD 83m), is looking to grow revenues through acquisitions and offering new services amid tough market conditions due to government cuts on nursing care reimbursement, he continued.</i></p>
<p>09- Mar Proteomics International seeks broader Asia-Pacific expansion after China entry - MD (Source: Proprietary Intelligence)</p>	<p><i>Proteomics International Laboratories, a privately owned Australian proteomics specialist, is actively seeking to expand into the Asia-Pacific region and will pursue deals once it has a solid footprint in China, said Founding Partner and Managing Director Richard Lipscombe. The Nedlands, Western Australia-based company, which expects to list on the ASX on 27 March with the proposed ticker PIQ, will enter The Philippines, Indonesia, Vietnam and Thailand in the near-term, Lipscombe told this news service. The emerging economies in the Middle East and some parts of South America and Western Europe are also on its radar, the MD continued. The company is unlikely to use advisors for its expansion strategy as it has an internal business development team, Lipscombe said. Proteomics is the large-scale mapping of the structure and function of proteins.</i></p>
<p>04- Mar Sompo Japan Nipponkoa to acquire 3.5% stake in Message for approximately JPY 2bn - report (translated) (Source: Nihon Keizai Shimbun)</p>	<p><i>Sompo Japan Nipponkoa Holdings Inc [TYO: 8630], a Japanese property insurance company, will spend about JPY 2bn (USD 16.8m) to acquire a 3.5% stake in Message Co., Ltd. [TYO: 2400], a Japanese nursing care home operator, the Nihon Keizai Shimbun reported. The acquisition is expected to be announced as early as 9 March, the unsourced Japanese language newspaper reported.</i></p>
<p>09- Mar Ranbaxy Laboratories/Sun Pharmaceutical Industries merger approved by High Court of Punjab & Haryana (Source: Stock Exchange Announcement (Edited))</p>	<p><i>India-based Ranbaxy Laboratories has informed the BSE that the Hon'ble High Court of Punjab & Haryana has orally pronounced an order on 09 March 2015 approving the Scheme of Arrangement involving Ranbaxy Laboratories' merger with Sun Pharmaceutical Industries under Sections 391 to 394, Sections 78 and 100 of the Companies Act, 1956, and Section 52 of the Companies Act, 2013. A certified true copy of the Order is awaited.</i></p>
<p>09- Mar Capital Mining agrees to pay AUD 7m in cash and AUD 25m in stock options to buy 49% stake in Broken</p>	<p><i>Capital Mining, the ASX-listed company, has agreed to pay AUD 7m (USD 5.39m) in cash and AUD 25m in stock options to buy a 49% stake in Broken Coast Cannabis, the Canadian medical marijuana business, the Australian Financial Review reported. According to the report, the reverse takeover will create the second listed medical marijuana company in Australia. The report cited Broken Coast's founder and</i></p>

	Coast Cannabis (Source: Australian Financial Review)	<i>general manager John Moeller as saying that the business hopes to become a market leader in Australia were policy makers are working to deal with regulatory change. The report said that the funds raised in Australia would help Broken Coast double its production capacity to 2m grams per year.</i>
07- Mar	Bota Bio to acquire 70% stake in Korea INsPharm for KRW 5.5bn (Source: Stock Exchange Announcement (Translated))	<i>Bota Bio, the listed South Korea-based IT company, announced that it has entered into an agreement to acquire a 70% stake in Korea INsPharm for KRW 5.5bn (USD 5m). Korea INsPharm is a privately held oriental medicine developer based in South Korea. The acquisition will be settled down with KRW 2bn in cash and the rest with a share swap. The transaction will be closed on 1 April 2015. Bota Bio has decided to acquire the target company in order to enter into new businesses.</i>
06- Mar	iKang Healthcare acquires 70% interest in WA Centers HK (Source: Company Press Release(s) (Edited))	<i>iKang Healthcare Group, Inc ("iKang" or the "Company") [NASDAQ:KANG], today (6 March) announced that it has acquired a 70% equity interest in WA Centers HK Limited ("WA Health Care"). Established in 2010, WA Health Care, a provider of high-end medical services, operates two medical centers in prime locations in Shanghai and Beijing. Since its establishment, WA Health Care has brought to the China market world-leading physicians, researchers and scientists in the fields of anti-aging medicine, functional medicine and regenerative medicine.</i>
06- Mar	Sotaravej Hospital to be acquired by Bangkok Chain Hospital (Source: Stock Exchange Announcement (Edited))	<i>Bangkok Chain Hospital [BKK: BCH], a Thailand-based hospital operator, has agreed to buy Thailand-based privately held Sotaravej Hospital, for about THB 400m (USD 12.3m), according to its stock exchange statement. Bangkok Chain Hospital Public Company Limited ("the Company") would like to notify that the Company has entered into the Assets Acquisition Agreement with Sotaravej Company Limited ("Sotaravej") on 6 March 2015 to acquire fixed assets of Sotaravej which operates the private hospital in Chachoengsao Province, namely Sotaravej Hospital with the transaction value of approximately THB 400 million. The transaction is subject to the result of the due diligence process. The Company will establish new subsidiary to acquire asset and to operate hospital. The Company will hold at least 75% in new subsidiary. The counter party in this transaction are not related party of the Company.</i>
06- Mar	Alvogen hunts for oncology and CNS buys in Thailand, Indonesia and Philippines, executive says (Source: Proprietary Intelligence)	<i>Alvogen, a privately owned Luxembourg-domiciled generics player, is actively seeking strategic acquisitions in Thailand, Indonesia and the Philippines, said Siegfried Gschliesser, vice president of commercial operations for Asia, on the sidelines of the World Generics Medicines Congress Europe in Madrid. The company is particularly interested in firms that are complementary to its business model. In terms of specific indications, the executive mentioned oncology and the central nervous system (CNS) indications are of interest in Asia.</i>
05 - Mar	Apollo Hospitals to continue 'string of pearls' acquisition strategy, CFO says (Source: Proprietary Intelligence)	<i>Existing clusters and tier-two cities would be of priority May tap PE for ventures such as Africa foray, or Apollo Health and Lifestyle Apollo Hospitals Enterprises [BSE:508869], the largest Indian hospital group, would look at further acquisitions in existing clusters and tier-two cities to increase market penetration and add new capabilities, said Chief Financial Officer Krishnan Akhileswaran. The company prefers a "string of pearls" strategy, instead of a "big-bang approach" with respect to an acquisition and at any point is evaluating half a dozen opportunities.</i>

05 - Mar	Mindray a logical take-private target; Citic PE denies rumors of approach (Source: Proprietary Intelligence)	<i>Mindray Medical International [Mai Rui Yi Liao; NYSE: MR] is a logical take-private target as it has been undervalued by US investors despite being one of China's largest medical device companies, industry sources said. Mindray has been approached by private equity firms for a take-private deal, including Citic PE, said two of the industry sources, who were both claiming some knowledge of the talks. Discussions with Citic PE have been ongoing from last year, one of them said. A spokesperson for Citic PE denied the firm has approached Mindray. The company is trading poorly compared to similar Chinese A-share listed companies, said an industry analyst.</i>
05- Mar	McKenzie Aged Care Group acquires Embracia portfolio (Source: Company Press Release*)	<i>McKenzie Aged Care Group is proud and excited to become the new owners and managers of seven Embracia homes and retirement villages. The seven residences are located across Victoria and Queensland: Embracia On Ashley - Reservoir, VIC Embracia In Lynbrook - Lynbrook VIC Embracia On The Peninsula - Rosebud VIC Embracia In Templestowe - Templestowe , VIC Embracia In Glasshouse Country - Beerwah, QLD Embracia On the Avenue - Deception Bay, QLD Embracia On Bribie - Bongaree, Bribie Island, QLD As well as two retirement villages, one on Bribie Island and one in Beerwah. Directors of McKenzie Aged Care Group, Sally and Mary Ann McKenzie are pleased that the company is delivering on a carefully planned growth strategy that puts people first.</i>
05- Mar	SanBio to launch IPO on 8 April (Source: Stock Exchange Announcement (Translated))	<i>SanBio, the Tokyo-based regenerative medicine biotech company, will launch an initial public offering on 8 April 2015, the Tokyo Stock Exchange announced today. A total of 6.5m shares will be offered, with Biovision LifeScience Fund 1 (a joint venture between Softbank Investment, Marubeni and others) offering 1.077m shares. There will also be an over-allotment of up to 975,000 shares. The lead underwriter for the IPO is Nomura Securities. The tentative pricing date is 10 March. Book building is from 23-27 March.</i>
05- Mar	Alcidion to raise capital for 1Q17 US entry, may need financial and legal advisors – exec (Source: Proprietary Intelligence)	<i>Alcidion Corporation, a privately owned health informatics technology company, is likely to raise capital in 3Q16 for its entry into the US and may need to retain financial advisors, said director Nathan Buzza. "We have major aspirations that by September 2016 the company will likely start raising a round of capital for our US market launch in January 2017," Buzza told Mergermarket. Alcidion is a provider of intelligent informatics for high performance healthcare that provides clinicians with decision support tools which also make recommendations about patient care, patient flow and their safety.</i>
05- Mar	Orthocell could need financial, legal advisors within a year for assets' divestment - chairman (Source : Proprietary Intelligence)	<i>Orthocell [ASX:OCC], a recently listed Australian regenerative medicine company, is likely to divest major assets over the coming year and will need to retain financial and legal advisors for the process, Chairman Stewart Washer said. While the company prefers to sell its entire portfolio in a block deal, it is probable that Ortho-ATI and Celgro in particular would be offloaded through a standard licensing transaction, Washer said. In such a deal, the suitor is likely to retain a minority equity stake in Orthocell as well as take on licensing, he added. However, the company will be reluctant to sell an equity stake nearing 19.99% – the mandatory takeover threshold – as it could deter interest from other suitors regarding its other assets, the chairman said. Orthocell last month expanded its presence in Asia, a key growth region for the company, with the first patients treated with its tendon repair therapy in Hong Kong, as reported.</i>

04- Mar Karex considers merger and acquisition opportunities (Source: The Edge Financial Daily)	<i>Karex, the listed Malaysian condom maker, is considering mergers and acquisitions, The Edge Financial Daily has reported. The report, citing company statement, said the company was looking for merger and acquisition opportunities to establish its own-brand business. The company recently announced a private placement exercise to raise MYR 150m (USD 41m) for cash reserves purposes.</i>
04- Mar Nexus6 appoints Bell Potter for IPO – report (Source: Australian Financial Review)	<i>Nexus6, New Zealand-based maker of Smartinhaler medical devices for respiratory diseases, has appointed Bell Potter Securities for its planned initial public offering, the Australian Financial Review reported. The company will use the IPO proceeds for product development and for Smartinhaler commercialisation, the newspaper reported, citing unnamed sources. Smartinhaler is used to ensure asthma patients abide by treatment protocols in clinical trials and in general use, according to the report. The company is seeking a cornerstone investor for the IPO, but will also make it available to retail and institutional investors, the report said.</i>
04- Mar Ageing, Disability and Home Care privatisation moving forward – report (Source: The Australian)	<i>The NSW state government is moving ahead with plans to privatise Ageing, Disability and Home Care (ADHC), the state-owned aged care and disability services operation, The Australian reported. The report cited unnamed sources as saying that expressions of interest for the unit were submitted last Friday. ADHC is thought to interest a number of major businesses, such as Bupa, Spotless, Transfield Services, and UK-based Serco, the report said. Several charities have also shown interest but may not have the financial capacity to buy the business, according to the newspaper.</i>
04- Mar Takeda Pharmaceutical to appoint Christophe Weber CEO effective 1 April (Source: Company Press Release(s))	<i>Takeda Pharmaceutical announced today the appointment of Christophe Weber as chief executive officer, effective 1 April. Takeda Pharmaceutical today announced that its Board of Directors decided to promote Christophe Weber, Representative Director, President & Chief Operating Officer (COO), to Representative Director, President & Chief Executive Officer (CEO), effective 1 April 2015. Yasuchika Hasegawa, Representative Director, Chairman of the Board & CEO, will assume the position of Representative Director, Chairman of the Board. The appointment is the result of a transparent and objective decision-making process endorsed by the Nomination Committee, which has been established as an advisory body to the Board of Directors and whose chairperson is an Outside Director.</i>
04- Mar Sumitomo Dainippon Pharma considering investments in M&A and others of up to JPY 100bn - report (translated) (Source: The Chemical Daily (Kagaku Kogyo Nippo))	<i>Sumitomo Dainippon Pharma, the listed Japan-based pharmaceutical company, is considering M&A investments on the scale of JPY 100bn (USD 836m), the Chemical Daily reported. The Japanese-language report disclosed, without, citing sources, that with the patent for its atypical antipsychotic drug Latuda set to expire in 2019, Sumitomo Dainippon Pharma expects to temporarily be hit by a reduction in sales volume. In order to attain the company's strategic goal of net sales of JPY 600bn by 2022, in addition to developing a new pipeline, it is considering M&A and other investments on the scale of JPY 100bn, the report said. No specific targets were revealed in the report.</i>
04- Mar GSK seeks buyer for Nicotinell – report (Source: Australian Financial Review)	<i>GlaxoSmithKline (GSK) is seeking a suitor for its Australian nicotine gum business Nicotinell, the Australian Financial Review reported. According to the report in the paper's Street Talk column, bids are anticipated before the end of March. GSK has engaged Greenhill to sell a number of assets globally as part of a wider AUD 8bn (USD 6.22bn) joint venture deal with Novartis, including smoking cessation products supplied by Novartis in Australia under Nicotinell and products sold under Australian private label agreements. The report noted that GSK and Novartis agreed</i>

		to sell the Nicotinell business after reaching a deal with the Australian Competition and Consumer Commission, which examined the JV last year and determined it would impact competition.
03- Mar	Shofu seeking acquisitions to boost core dental business (Source: Proprietary Intelligence)	Shofu (TYO: 7979) a listed Kyoto, Japan-based dental products manufacturer, is seeking to acquire smaller peers in Japan and the US, and distributors in Brazil, India and Southeast Asia, the company's IR representative Yusuke Hidaka said. The JPY 23bn (USD 192m) market cap company is seeking to nearly triple its sales and increase operating profit sevenfold by 2022.
03- Mar	HUIINNO to raise USD 10m Series A funding by 2015 end for mass medical devices' production – CEO (Source: Proprietary Intelligence)	<p>HUIINNO, the South Korea-based wearable healthcare devices manufacturing company, is planning to raise USD 10m Series A funding by the end of 2015, said founder & CEO Yeongjoon Gil. The capital raise is aimed to allow mass production of its wearable blood pressure monitoring device, and will follow the ongoing USD 2m seed funding round that will be closing in March 2015.</p> <p>Its competitors include Sotera Wireless's Visi Mobile, Withings, HealthSTATS's Bpro and Samsung Electronics, according to the company's report. The company has an overseas branch in New York Gil noted. HUIINNO was initially founded in June 2014 in the US and it set up its South Korean office a month later, Gil noted. Gil is the largest shareholder with majority stake, Gil said.</p>
03- Mar	Optos suitor Nikon first approached over collaboration in December (Source: Proprietary Intelligence)	Japanese optics and imaging company Nikon [TYO:7731] made its initial approach for bid target retinal imaging firm Optos [LON:OPTS] in December last year, a source close and a person familiar with the situation told this news service. The parties started talks about a possible collaboration around year-end, and this later led to the recommended GBP 340 per share cash offer for Optos, the person familiar said. Optos, whose shares last closed at GBP 344p, has not been in talks with any other potential suitors, a second person familiar said. A spokesperson for Nikon declined to comment on how or when deal talks began.
03- Mar	GSK's opiates business in Australia to be acquired by India's Sun Pharma (Source Stock Exchange Announcement(s) (Edited))	GlaxoSmithKline (GSK) and Sun Pharmaceutical Industries Ltd. (Reuters: SUN BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma") today announced that their respective wholly owned subsidiaries have reached an agreement related to GSK's Opiates business in Australia. The current GSK Opiates business including related manufacturing sites in Latrobe (Tasmania) and Port Fairy (Victoria) and its portfolio of opiates products along with inventory, will transfer to a subsidiary of Sun Pharma. The product portfolio consists of poppy-derived opiate raw materials that are primarily used in the manufacture of analgesics for the treatment of moderate to severe pain. All employees from both sites will also be offered employment by Sun with the Opiates business. The financial terms of the transaction are confidential.
02- Mar	Narayana Health eyes acquisitions in oncology and cardiology - Director (Source Proprietary Intelligence)	Narayana Health, an India-based hospital operator, is eyeing acquisitions with a focus on cancer and heart care, Director and Senior Vice President Viren Shetty said. The Bangalore, India-based company would focus on north and east India for acquisitions, he added. In November 2014, the company acquired West Bengal-based West Bank Hospitals for INR 1.5bn (USD 24m), as previously reported. In January 2015, UK's CDC Group invested USD 50m as part of a pre-IPO round which was used to pare down company debt, Shetty said. Proceeds from the CDC

fundraise also helped with the West Bank Hospital acquisition, he noted. Shetty declined to comment on the IPO.

02- Mar <i>Qualitas to decide on its IPO by this week – report (Source: The Edge Financial Daily)</i>	<i>Qualitas Healthcare, the Malaysian healthcare provider, will decide by this week whether to proceed with an IPO or to sell off its business to interested parties, The Edge Financial Daily reported. The report, citing an unnamed source, said that negotiations were still being carried out between the Malaysian healthcare provider and other parties on the matter and a decision could be reach this week.</i>
02- Mar <i>Medservice Plus seeks JV deals for emerging market entry – Chairman (Source: Proprietary Intelligence)</i>	<p><i>Privately held drugs distributor Medservice Plus is seeking overseas expansion as part of an ongoing globalization strategy, Chairman Zhanat Umarov said. The Kazakhstan-based company’s preferred expansion vehicle will be through joint ventures (JVs). This is because foreign players are typically not allowed to act “solo” in some local pharma markets as the sector is generally seen as strategically vital, the executive said.</i></p> <p><i>Using acquisition model to enter the Brazilian market has an advantage over using a JV as the former enables foreign players to hit the ground running, while the latter may drag on for a long time, Monteiro explained. He estimated a one year timeframe to obtain all the necessary local approvals to establish a new drug distributor and get its products launched. Medservice manned by over 1,000 workers, supplies drugs to over 2,500 pharma retail outlets and healthcare facilities throughout Kazakhstan, according to its official website.</i></p>
02- Mar <i>7lk.cn raises CNY 300m in Series A fundraising (translated) (Source: China.com.cn)</i>	<i>7lk.cn [Qi Le Kang], a China-based, privately owned, online medicine retailer, has raised a total of CNY 300m (USD 47.8m) from investors including Qidi Capital, Govtor Capital, Shanghai Grand Yangtze Capita, China.com reported citing Lai Yurui, the CEO.</i>
02- Mar <i>Nanjing Real Pharmaceutical 95% stake asking price lowered to CNY 132.85m (Source Stock Exchange Announcement (Translated))</i>	<i>Nanjing Textiles Import & Export [Nan Fang Gu Fen, 600250.SH], a listed Chinese textiles trading company, has decided to lower the asking price on a 95% stake in Nanjing Real Pharmaceutical [Rui Er Yi Yao] to CNY 132.85m (USD 21.2m). As reported, the stake was put up for sale on the Nanjing Assets and Equity Exchange by Nanjing Textile Import & Export at an initial bidding price of CNY 147.61m (USD 23.614m). However, as of 28 February, no potential bidder had expressed an interest in bidding for the stake. Nanjing Real Pharmaceutical, a Jiangsu-based company, is engaged in the production and sale of medicines. It has a registered capital of CNY 40m.</i>
02- Mar <i>Guizhou Xinbang Pharmaceutical will continue share trading halt, planning significant assets restructuring (Source: Stock Exchange Announcement (Translated))</i>	<i>Guizhou Xinbang Pharmaceutical [Xin Bang Zhi Yao, 002390.SZ], a Guizhou-based, listed Chinese pharmaceutical company, will continue its share trading halt on 3 March due to planning a significant assets restructuring. The company is expecting to resume share trading by 2 April after the draft plan or deal book is disclosed. The company has halted its share trading since 16 February 2015 over a major event. It has a market cap of CNY 12.436bn (USD 1.983bn).</i>

01- Mar *Health Care presented to buyers including Fosun, IHH, and Bangkok Dusit, formal sale not yet underway - report (Source: Australian Financial Review)*

Health Care, the Australian hospital operator, has been presented to buyers including Fosun, IHH and Bangkok Dusit by its owner Archer Capital, the Australian Financial Review reported. According to the report in the paper's Street Talk column, which cited unnamed sources, Archer has not launched a formal sales process but has started pitching the company to possible suitors. The item noted that meetings took place over the last few months and represented preliminary talks ahead of a potential sale later this year. The paper stated that Australian hospital operators Ramsay Health Care and Health scope may be interested in Health Care. Health Care controls 16 hospitals.

DISCLAIMER

This Information Package is distributed by Quadria Capital Investment Management ('Quadria Capital') upon the express understanding that no information herein contained is proprietary or has been independently verified. Further, no representation or warranty expressed or implied is made nor is any responsibility of any kind accepted with respect to the completeness or accuracy of any information. Also, no representation or warranty is expressed or implied is made that such information in any respect as of any date or dates after those stated herein with respect to any matter concerning any statement made in this Information Package. Quadria Capital and its Managing Partners, employees, agents and consultants shall have no liability (including liability to any person by reason of negligence or negligent misstatement) for any statements, opinions, information or matters (express or implied) arising out of, contained in or derived from, or for any omissions from the Information Package. All recipients of the Information Package should make their own independent evaluations and should conduct their own investigation and analysis and should check the accuracy, reliability and completeness of the Information and obtain independent and specific advice from appropriate professional advisers, as they deem necessary.

Where this Information Package summarizes the provisions of any other document, that summary should not be relied upon and the relevant documentation must be referred to for its full effect.

QUADRIA
CAPITAL

Abrar Mir
Managing Partner

Quadria Capital Investment Management Pte. Ltd.
3 Pickering Street, #01-68 Nankin Row, Singapore - 048 660
D +65 6221 6939 M +65 8522 1033
abrar.mir@quadriacapital.com | www.quadriacapital.com

QUADRIA
CAPITAL

Amit Varma
Managing Partner

Quadria Capital Investment Advisors Pvt. Ltd.
D1 Clarion Collection, The Qutab Hotel Complex, Shaheed Jeet Singh
Marg, New Delhi – 110 016
D +91 11 4194 5507 M +91 98 1838 5665
amit.varma@quadriacapital.com | www.quadriacapital.com